Copyright
©The Author(s) 2017.
World J Hepatol. Feb 18, 2017; 9(5): 252-262
Published online Feb 18, 2017. doi: 10.4254/wjh.v9.i5.252
Published online Feb 18, 2017. doi: 10.4254/wjh.v9.i5.252
Table 4 Treatment tolerability (simeprevir)
| Patients aged < 66 | Patients aged ≥ 66 | P value | |
| Initial doses (median, range) | |||
| PEG-IFNα2a (180/90) (μg/wk) | 19/0 | 10/1 | 0.366 |
| PEG-IFNα2b (120/100/80/others) (μg/wk) | 2/16/5/1 | 0/25/5/1 | 0.422 |
| SMV/BW (mg/kg per day) | 1.6 (1.1-2.5) | 1.8 (1.3-2.7) | 0.011 |
| RBV/BW (mg/kg per day) | 11.6 (6.8-17.1) | 12.3 (6.0-20.6) | 0.166 |
| Dose reduction, n (%) | |||
| PEG-IFN | 5 (13.5) | 6 (15.3) | 1 |
| SMV | 0 | 0 | 1 |
| RBV | 3 (8.1) | 6 (15.3) | 0.481 |
| Discontinuation, n (%) | |||
| PEG-IFN | 5 (13.5) | 5 (12.8) | 1 |
| SMV | 2 (5.4) | 2 (5.1) | 1 |
| RBV | 11 (29.7) | 23 (58.9) | 0.012 |
| Adherence, mean ± SD (%) | |||
| PEG-IFN | 93.6 ± 16.8 | 92.3 ± 19.5 | 0.592 |
| SMV | 98.1 ± 7.2 | 93.9 ± 18.1 | 0.079 |
| RBV | 91.0 ± 16.1 | 86.8 ± 20.2 | 0.126 |
- Citation: Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Wakabayashi H, Ohkoshi S, Tsukishiro T, Takahashi T, Watanabe T, Terai S. Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C. World J Hepatol 2017; 9(5): 252-262
- URL: https://www.wjgnet.com/1948-5182/full/v9/i5/252.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i5.252